GlycoDisplay develops new sugar design for the treatment of lysosomal diseases
Nature Communications has published the results of GlycoDisplays’ work; please read the original article here.
Lysosomal enzymes are decorated with structures of sugar, which determine how long time the enzymes will circulate in the body and which organs they will reach. GlycoDisplay has changed the natural structures of sugar and developed an improved design of the sugar, which prolongs the time of effect for the enzymes and makes it possible to target the heart and maybe even the brain where this is important for the optimal treatment.
The scientific results show that the new sugar design improves the effect of the enzyme in sick mice. GlycoDisplay now aims to develop the improved version of the present enzyme replacement therapy for the treatment of Fabry Disease. The company will also apply the new developed sugar design to other lysosomal diseases to treat diseases that affect the brain.
GlycoDisplay is a spinout from Copenhagen Center for Glycomics at the University of Copenhagen and works to optimize sugar structures on glycoproteins. Based on the new so-called LAGD concept (Long-Acting Glycodesign) GlycoDisplay will now work on its own sugar optimized drug candidates, which may be brand new drugs or improved versions of existing drugs (Biobetters).
Lysosomal diseases and enzymes
Lysosomal diseases are rare metabolic diseases characterized by lack of enzymes to break down waste products that will accumulate in the body’s organs and lead to invalidating failure of the organs and early death. The treatment is enzyme replacement therapy, which has been partly successful. The present enzyme replacement therapy, however, does not reach all organs affected by the disease, which means that many patients do not receive an effective treatment. There is a huge need for improved enzyme replacement therapies for these rare genetic diseases, which often affect children.